-
Thekla Antoniadou
First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, ATTIKON University Hospital, Athens, Greece
-
George Archontakis
First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, ATTIKON University Hospital, Athens, Greece
-
Ioannis Kapsimalis
First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, ATTIKON University Hospital, Athens, Greece
-
Leonidas Dimopoulos
First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, ATTIKON University Hospital, Athens, Greece
-
Vassilios G. Igoumenou
First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, ATTIKON University Hospital, Athens, Greece
-
Panayiotis D. Megaloikonomos
First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, ATTIKON University Hospital, Athens, Greece
-
Andreas F. Mavrogenis
First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, ATTIKON University Hospital, Athens, Greece
Keywords:
Erdheim-Chester disease; Non-Langerhans cell histiocytosis; Interferon A
Abstract
Erdheim-Chester disease is a rare non-Langerhans cell histiocytic disorder characterized by abnormal multiplication of histiocytes or tissue macrophages. It is most commonly characterized by multifocal osteosclerotic lesions of the long bones demonstrating sheets of foamy histiocytes, with or without histiocytic infiltration of extraskeletal tissues such as the skin, pituitary gland, retroperitoneum, kidneys and heart. Most cases are diagnosed in adulthood, between ages 40 and 60 years (mean, 53 years), with a 3-fold frequency in males than females. Sporadic cases in children have been reported. This review discusses the clinicopathological features, diagnosis and current treatment of this rare, non-Langerhans cell histiocytosis.
Downloads
Download data is not yet available.